Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 17Completed 8Recruiting 5Withdrawn 2Not yet recruiting 2Unknown 1Terminated 1Suspended 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 7Colorectal Neoplasms 3Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mouth Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Liposarcoma 1Leukemia, Plasma Cell 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Biopsy × Clear all
NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡